1. IDEAYA to present at RBCCM Ophthalmology Conference on April 3, 2025. 2. Participation in Stifel 2025 Virtual Targeted Oncology Forum on April 8, 2025. 3. Live audio webcast of events will be accessible on IDEAYA's website. 4. Company focuses on targeted therapeutics through precision medicine and molecular diagnostics. 5. IDEAYA emphasizes drug discovery capabilities related to synthetic lethality.
Participation in investor events often raises investor interest. IDEAYA's focus on precision medicine aligns with market trends boosting stock performance.
Investor presentations typically enhance visibility and investor confidence, impacting IDYA positively. The precision medicine focus aligns with growing market demand.
Immediate events may attract investor interest, potentially increasing stock prices. Historical trends show similar impacts during conference participations.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events.
Thursday, April 3rd, 2025 at 11:30 AM ET
Tuesday, April 8th, 2025 at 12:00 PM ET
A live audio webcast of the conference events, as permitted by the conference host, will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcast will be accessible for 30 days following the live event.
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 18, 2025.
IDEAYA Biosciences
Andres Ruiz Briseno
Chief Accounting Officer
[email protected]
SOURCE IDEAYA Biosciences, Inc.